FMP
BELLUS Health Inc.
BLU
NASDAQ
Inactive Equity
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
14.75 USD
0.005 (0.03391%)
About
ceo
Mr. Roberto Francesco Bellini
sector
Healthcare
industry
Biotechnology
website
https://www.bellushealth.com
exchange
NASDAQ
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
CIK
0001259942
ISIN
CA07987C2040
CUSIP
07987C204
Address
275 Armand-Frappier Boulevard
Phone
14506804500
Country
CA
Employee
74
IPO Date
Oct 27, 2000
Key Executives
